Moderna enrolled 3,732 kids ages 12 to 17 in its trial, and two-thirds received two doses of the vaccine. Fourteen days after both doses, the vaccine was 100 percent effective at preventing symptomatic COVID-19. The shot was 93 percent effective against symptomatic disease 14 days after a single dose.
There were no significant safety concerns, and side effects were consistent with what has been seen in adults receiving the vaccine, including injection site pain, headache, fatigue and muscle pain.
Moderna plans to submit its clinical trial data to regulators in early June.
Read Moderna’s full news release here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
